Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Non-hepatic metabolic conditions represent crucial drivers of post-liver transplant morbidity and mortality.
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of a heterogeneous disease intricately linked with metabolic disorders.
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.